Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144645 | 0.84 | MAPK1 (0.38) | MAPK1KMT2AELANEKDM4ENR4A2 | |
| SCHEMBL31522409 | 0.81 | ACSS2 (0.45) | MAPK1KMT2AELANEKDM4EALDH1A1 | |
| SCHEMBL16025801 | 0.81 | ELANE (0.44) | MAPK1KMT2AELANEKDM4EALDH1A1 | |
| SCHEMBL27623744 | 0.80 | BACE1 (0.36) | MAPK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL14895637 | 0.80 | MAPK1 (0.47) | MAPK1ELANEKDM4EALDH1A1PKM | |
| SCHEMBL2861533 | 0.79 | ELANE (0.35) | MAPK1KMT2AELANEKDM4ENR4A2 | |
| SCHEMBL13927673 | 0.77 | KMT2A (0.38) | KMT2AELANENR4A2PKMMAPT | |
| SCHEMBL4144371 | 0.77 | NTSR1 (0.37) | MAPK1KMT2AKDM4ENR4A2ALDH1A1 | |
| SCHEMBL20916785 | 0.76 | MAPK1 (0.37) | MAPK1KMT2AELANEKDM4EALDH1A1 | |
| SCHEMBL4139741 | 0.74 | VCAM1 (0.34) | KMT2AKDM4EALDH1A1MEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | MAPK1 7/4885KMT2A 810/4885ELANE 3610/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | MAPK1 6/4885KMT2A 741/4885ELANE 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.